Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year
Allschwil, Switzerland, November 20, 2023
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. (NYSE: PFE, “Pfizer”) in the Asia Pacific region and China exceeded the sales threshold triggering a further USD 1.25 million milestone payment.
David Veitch, Basilea’s Chief Executive Officer, stated: “This marks the third sales milestone payment for Asia Pacific and China this year. It highlights that Cresemba continues to serve a high medical need and also reflects the significant commercial potential of Cresemba in this region. We are pleased to see that Cresemba is well on track to become a leading global brand for the treatment of patients with invasive mold infections.”
The license agreement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic countries) as well as 16 countries in the Asia Pacific region and China.
Cresemba is approved in 76 countries to date and is currently marketed in 71 countries, including the United States, most EU member states and additional countries inside and outside of Europe. According to the latest available market data, total global in-market sales of Cresemba in the twelve months between July 2022 and June 2023 amounted to USD 421 million, a 19 percent growth year-on-year.1
About Isavuconazole (Cresemba®)
Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba®. Basilea has entered into several license and distribution agreements for isavuconazole covering approximately 115 countries. In the 27 European Union member states, as well as in Iceland, Liechtenstein, Norway and the U.K., isavuconazole is approved for the treatment of adult patients with invasive aspergillosis and for adult patients with mucormycosis for whom amphotericin B is inappropriate.2 In China, the oral and intravenous formulations are approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. Isavuconazole is also approved in the United States and several additional countries in Europe and beyond, including Japan.3 It has orphan drug designation in the US, Europe and Australia for its approved indications.
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
|Peer Nils Schröder, PhD|
Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica Ltd, Allschwil
|Phone||+41 61 606 1102|
This press release can be downloaded from www.basilea.com.
- IQVIA Analytics Link, June 2023. In-market sales reported as moving annual total (MAT) in US dollar.
- European Public Assessment Report (EPAR) Cresemba: http://www.ema.europa.eu [Accessed: November 19, 2023]
- The registration status and approved indications may vary from country to country.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Festi hf.: Major shareholder announcement from Stefnir hf.6.12.2023 16:14:46 CET | Press release
Please see attached major shareholder announcement. Attachment 20231206 Stefnir Flöggun FESTI
Wistar Scientists Identify Esophageal Cancer Biomarkers6.12.2023 16:09:10 CET | Press release
Dr. Noam Auslander and authors trained a neural network to identify cancer risk from microbes Philadelphia, PA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wistar scientists have developed a new tool that can help identify cancer-associated microbes by using machine learning technology. Under the leadership of Dr. Noam Auslander — assistant professor in the Ellen and Ronald Caplan Cancer Center’s Molecular & Cellular Oncogenesis Program — the group has analyzed short read RNA-sequencing data to detect biomarkers for esophageal carcinoma, or ESCA. Their paper, “Microbial gene expression analysis of healthy and cancerous esophagus uncovers bacterial biomarkers of clinical outcomes,” was published in International Society for Microbial Ecology Communications. Tumor microenvironments are often analyzed using RNA sequencing, or RNAseq, which identifies mRNA in a population of cells to find which genes are being expressed. Theoretically, RNAseq data can reveal the expression of microbial genes in canc
The Cadmium Yellow Alert: Study Explains the Rapid Deterioration of One of Juan Mirò’s Favourite Colours6.12.2023 15:57:37 CET | Press release
Researchers from the Politecnico di Milano and Ca' Foscari University of Venice are part of the team unravelling the causes of the degradation of cadmium yellow, used by the Spanish painter: the presence of zinc in the crystalline matrix of the pigment, the production process and the environmental conditions in which paint was stored. The research is published in the scientific journal Heritage Science. MILAN, Italy, Dec. 06, 2023 (GLOBE NEWSWIRE) -- A photo from 1978 shows famous Catalan surrealist painter Juan Miró in his Taller Sert, surrounded by his paintings. In the background, the bright, intense yellow of Femme dans le rue (1973), stands out. Fifty years later, that cadmium-based yellow is faded and chalky. The same phenomenon has affected 25 other paintings in the Fundació Miró Mallorca. The degraded yellow paint used by Mirò is made from cadmium yellow, a modern pigment composed of cadmium sulfide and introduced in the late 19th century. The pigment was used extensively by ar
Baltic Horizon Fund general meeting of investors and a notice to convene a new general meeting of investors6.12.2023 15:20:00 CET | Press release
Extraordinary General Meeting (hereinafter the “General Meeting”) of Baltic Horizon Fund unit-holders and Swedish Depositary Receipt (hereinafter the “SDR”) holders (hereinafter together the “Investors”) took place on 6 December 2023 in Tallinn, Estonia. Proposed agenda of the meeting was the following: Decision to elect Reimo Hammerberg as a new member of the supervisory board of Baltic Horizon Fund as of 1 January 2024 for an indefinite period.Decision to pay remuneration to Reimo Hammerberg for fulfilling obligations of the member of the supervisory board in the amount of EUR 16,000 per calendar year.Decision to elect Monica Hammer as a new member of the supervisory board of Baltic Horizon Fund as of 1 January 2024 for an indefinite period.Decision to pay remuneration to Monica Hammer for fulfilling obligations of the member of the supervisory board in the amount of EUR 11,000 per calendar year.Decision to elect Per V. Jenster as a new member of the supervisory board of Baltic Horiz
Vicinity Showcased Industrial 5G Solution in 5G-ACIA Industrial 5G day6.12.2023 15:08:22 CET | Press release
TAIPEI, Taiwan, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Vicinity Technologies Limited (Vicinity) showcases the advanced industrial 5G solution in the 5G Alliance for Connected Industries and Automation (5G-ACIA) Industrial 5G Day 2023, being held in Taipei, Taiwan on 7th December 2023. Vicinity is demonstrating a low latency industrial 5G wireless networking solution to enable industrial safety applications in factories with 5G connected Automatic Guided Vehicles (AGV). Vicinity developed 5G integrated small cell (ISC) network wirelessly connects an emergency stop controller with the AGVs. The demonstration emulates an emergency scenario where the stop button is activated. The AGVs are stopped with the latency within 3ms. The response time is 200 times faster compared with the conventional 5G mobile networks. To achieve such a fast response time, the ISC supports the User Plane Function (UPF) offloading. This allows the user application running on the ISC to minimise the latency. The ISC is